ABSTRACT
INTRODUCTION
Acinetobacter meningitis is a rare complication following neurosurgical procedures. Currently, Acinetobacter is the second most common agent of nosocomial meningitis in some hospitals. 1 The mortality rate is high and those who outlive the infectious episode usually have severe neurological defi cits. 2 The estimated 15% mortality rate of nosocomial meningitis 3 increases to 40% if caused by Acinetobacter. 4 In developing countries, it can reach up to 70%. 5 There have been no randomized controlled studies conducted to evaluate different treatments for Acinetobacter meningitis. The current treatment regimen is based on case reports and pharmacological data.
Intrathecal therapy remains controversial due to divergent outcomes. The aim of this study was to evaluate the risk factors associated with treatment failure of nosocomial Acinetobacter meningitis in a cohort from a Brazilian hospital.
METHODS
The hospital records of 22 patients diagnosed with nosocomial Acinetobacter meningitis admitted from January 2006 to January 2009 were retrospectively reviewed. Inclusion criteria were: (i) clinical evidence of central nervous system infection, (ii) isolation of A. baumannii from cerebrospinal fl uid, and (iii) acquisition of the infection more than 72 hours after hospital admission. Central nervous system infection was defi ned as increased white cell count (> 50% polymorphonuclear leucocytes), increased protein and/or decreased glucose (< 15 g/dL) in cerebrospinal fl uid. A. baumannii identifi cation without cerebrospinal fl uid alterations was considered contamination/colonization. 1 Variables abstracted from the patient record, summarized in Table 1 and 2, were: gender, age, cerebrospinal fl uid (number of leukocytes/mm 3 , glucose, and protein levels), history of trauma, presence of external shunt at the time of meningitis diagnosis, days of admission before infection and total length of hospital stay, elective surgery, previous use of antibiotics, susceptibility tests for Acinetobacter, antibiotic therapy (intravenous and intrathecal) used, and patient outcome. Acinetobacter baumannii was identified using biochemical methods. Antibiotic susceptibility was assayed by diffusion disc according to CLSI. 6 Appropriate therapy was defined as administration of one or more active agents against A. baumannii in adequate doses and routes of administration.
Patient outcome was deemed successful if the patient had been discharged from hospital without re-admission within the following three months. All other outcomes were considered failure.
Statistical analyses were performed using the SPSS software (version 11; Chicago, IL, USA). Distribution of variables in the surviving and non-surviving groups was assessed by χ 2 test or Fishers exact test for categorical variables, and by the Mann-Whitney test for continuous variables. Variables significantly associated with mortality in univariate analysis will be included in a binary multivariate logistic regression model. 
RESULTS
In this case study, we report 22 cases of meningitis caused by A. baumannii. The mean age of patients was 43.6 year (21 to 91) and 54.5% were male. Cerebrospinal fl uid culture grew A. baumannii within 60 days of admission, and the mean length of hospital stay was 18.2 days. Patients and cerebrospinal characteristics are described in Table 1 . Two patients were excluded due to contamination/colonization. All cases had previous neurosurgery procedures, including elective surgery (27.3%), external shunt (54.5%), and emergency surgery due to trauma (18.1%).
Antibiotic susceptibility pattern of isolated A. baumannii is described in Table 2 . Susceptibility to imipenem and ampicillin/sulbactam was ascertained in 13 (59%) and 16 (73%) of the isolates, respectively. The fatality rate among ANM patients was of 72.7%. None of the evaluated risk factors was signifi cantly associated to patient mortality. Out of 22 patients, only 17 (77.2%) received treatment, including two patients who received intrathecal therapy in addition to systemic antibiotics. The reason for abstaining from antimicrobial treatment in four cases was death
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Treatment of A. baumannii is an issue of concern, specifi cally because of the increasing prevalence of carbapenem resistance and colistin and polymyxin use. In our study, treatment with carbapenem would have failed in more than 40% of cases. The reason for the failure attributed to carbapenems is not clear. A. baumannii showed increased susceptibility to sulbactam. In our hospital, all strains were routinely tested using the diffusion disc assay for polymyxin susceptibility, but this method is not reliable. Sulbactam is an effective drug against Acinetobacter, as confi rmed by in vitro and in vivo studies, as well as by several clinical trials. 10 However, physicians continue to avoid this drug, preferring colistin/polymyxin. Resistance to polymyxins is rare, even in a hospital with high incidence of carbapenem-resistant P. aeruginosa, although some cases have been published. 11 before final culture results. Appropriate antibiotic therapy was initially administered to 100% of the surviving patients, whereas only 69% (9/16) of patients who did not survive received it. There was no significant difference between survivors or therapies (OR = 5.15; IC = 0.45-54.01). Ventricular shunts were removed from all patients with confi rmed meningitis.
DISCUSSION
The mortality rate observed in this study was high (73%). Mortality rates ranging from 30%-70% have been previously reported and are generally higher in developing countries. 4, 5, 7, 8 Studies assessing the mortality rate associated with meningitis have confi rmed higher mortality rates associated with Acinetobacter as compared to other Gramnegative bacilli. Polymyxins penetrate the cerebrospinal fl uid and produce sustained bactericidal concentrations. Intrathecal therapy further improves patient outcomes. 12 Association of antibiotics have been suggested to improve patient outcome, but the literature regarding this issue is scarce. 7, [13] [14] [15] Rifampicin and aminoglycosides are drugs that can be used in association with polymyxins or carbapenems.
4,9
Tigecycline is a therapeutic option; however, its effectiveness for meningitis has not been studied yet. Wadi and Rub published an ANM case successfully treated with tigecycline. 16 Pharmacokinetic and pharmacodynamic data indicate that tigecycline blood concentrations seem to be suboptimal for exerting maximal antibacterial activity at this compartment. Aggressive treatment of A. baumannii meningitis using a multidrug regimen, including intrathecal therapy, appears to be indicated. In our study, only two patients were treated with intrathecal therapy. This could be one explanation for the high mortality rate. In a recent review, intrathecal plus systemic therapy was recommended for treatment of ANM patients. 17 Risk factors are important in predicting the outcomes of ANM patients. A case-control study showed a higher incidence of hydrocephaly in patients with Acinetobacter. 8 Although not technically defi ned as a risk factor, previous colonization with Acinetobacter is thought to increase risk of developing ANM. [18] [19] [20] In our institution, A. baumannii is the most common cause of ventilator-associated pneumonia and is commonly isolated from several sites in the patient.
In conclusion, Acinetobacter meningitis is a hazardous infection in neurosurgery units. Actions aiming at reducing post-surgery or shunt infection must be evaluated routinely. The high mortality rate observed in our study suggests the need for treatment with active agents against Acinetobacter, especially in settings where this microorganism is endemic. It is also recommended the addition of intrathecal therapy after identifi cation of the bacterium. Prospective trials with intrathecal and intravenous colistin could help defi ning an appropriate therapy for A. baumannii meningitis.
